NCT01903824View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

December 31, 2013

Conditions
Cognitive Impairment
Interventions
DRUG

CEP-26401

CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.

DRUG

donepezil hydrochloride

Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated

DRUG

modafinil

modafinil 200 mg tablet, over-encapsulated

DRUG

Placebo

Placebos formulated to match each active drug

Trial Locations (1)

Unknown

Teva Investigational Site 38051, Leiden

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01903824 - Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects | Biotech Hunter | Biotech Hunter